RECIST 1.1, mRECIST, and Choi criteria for evaluating treatment response and survival outcomes in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab-Reference-Cited by-同舟云学术

RECIST 1.1, mRECIST, and Choi criteria for evaluating treatment response and survival outcomes in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab

Published:2024-07-30 Issue: Volume: Page:
ISSN:1432-1084
Container-title:European Radiology
language:en
Short-container-title:Eur Radiol

Author:

Kim Dong Hwan,Min Eun Jeong,Kim Bohyun^ORCID,Choi Jong Young,Jang Jeong Won,Sung Pil Soo,Han Ji Won,Kim Hokun,Choi Joon-Il

Funder

Catholic Medical Center Research Foundation

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00330-024-10986-z.pdf

Reference28 articles.

1. Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of Incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249

2. Reig M, Forner A, Rimola J et al (2022) BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol 76:681–693

3. NCCN Clinial Practice Guideline in Oncology—Hepatocellular Carcinoma (version 1.2023) (2023) National Comprehensive Cancer Network. Hepatocellular Carcinoma (version 1.2023). Available via https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1514. Accessed 15 Jun 2023

4. European Association for the Study of the Liver. Electronic address EEE, European Association for the Study of the Liver (2018) EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 69:182–236

5. Park JW, Chen M, Colombo M et al (2015) Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int 35:2155–2166